Uyterlinde A M, Schipper N W, Baak J P, Peterse H, Matze E
Pathological Institute, Free University Hospital, The Netherlands.
Am J Clin Pathol. 1988 Mar;89(3):301-7. doi: 10.1093/ajcp/89.3.301.
This retrospective study evaluates several prognostic factors in 63 patients with invasive ductal breast cancer. Special attention is paid to the additional prognostic value of cellular DNA content to the previously developed and evaluated quantitative features mitotic activity index (MAI) and multivariate morphometric prognostic index (MPI). Follow-up was monitored for at least 50 months (median survival, 78 months) and only patients who died of distant metastases were included. The results show that the MAI is the strongest prognostic factor of all single features (Mantel-Cox, P = 0.008). Although patients with a diploid or tetraploid tumor tended to have a better prognosis than those with an aneuploid cancer, the DNA index as a single parameter was a weak prognosticator in the univariate survival analysis (Mantel-Cox, P = 0.24). Within the diploid and tetraploid tumors the MAI could distinguish patients with a favorable and unfavorable prognosis prediction (chi-square, P = 0.01). For aneuploid tumors this was not possible. Analysis of combined features revealed that the MPI has a high prognostic value (Mantel-Cox, P = 0.0015), thus confirming other studies. A linear combination of the nuclear DNA index, MAI, nodal status, and mean nuclear area showed only a slight improvement in prognosis prediction compared with the MPI (Mantel-Cox, P = 0.0005); with this rule, the classification of the patients was more in agreement with the actual outcome in 4% of the cases. The gain was in the poor prognosis group. These results suggest that the additional prognostic value of nuclear DNA content is restricted when compared with the morphometric prognostic factors. Further studies on a larger number of patients are required to confirm these findings.
这项回顾性研究评估了63例浸润性导管癌患者的多个预后因素。特别关注细胞DNA含量相对于先前开发和评估的定量特征——有丝分裂活性指数(MAI)和多变量形态计量预后指数(MPI)的额外预后价值。随访时间至少为50个月(中位生存期为78个月),仅纳入死于远处转移的患者。结果表明,MAI是所有单一特征中最强的预后因素(Mantel-Cox检验,P = 0.008)。尽管二倍体或四倍体肿瘤患者的预后往往比非整倍体癌患者更好,但在单变量生存分析中,DNA指数作为单一参数的预后价值较弱(Mantel-Cox检验,P = 0.24)。在二倍体和四倍体肿瘤中,MAI能够区分预后良好和不良的患者(卡方检验,P = 0.01)。对于非整倍体肿瘤则无法做到这一点。对联合特征的分析显示,MPI具有较高的预后价值(Mantel-Cox检验,P = 0.0015),从而证实了其他研究结果。与MPI相比,核DNA指数、MAI、淋巴结状态和平均核面积的线性组合在预后预测方面仅略有改善(Mantel-Cox检验,P = 0.0005);按照此规则,在4%的病例中患者分类与实际结果更相符。获益的是预后不良组。这些结果表明,与形态计量预后因素相比,核DNA含量的额外预后价值有限。需要对更多患者进行进一步研究以证实这些发现。